30484-77-6 Usage
Uses
Used in Pharmaceutical Industry:
Flunarizine dihydrochloride is used as an antipsychotic and H1 antihistamine for its calming effects and to alleviate symptoms of allergies.
Used in Neurology:
Flunarizine dihydrochloride is used as an anticonvulsant for the treatment of epilepsy, as it helps to control epileptiform activity.
Used in Migraine Prophylaxis:
Flunarizine dihydrochloride is used as a preventive measure for migraines, reducing the frequency and severity of migraine attacks.
Used in Cerebral and Peripheral Vasodilation:
Flunarizine dihydrochloride is used as a vasodilator in both the cerebral and peripheral vascular systems, improving blood flow and reducing the risk of blood flow disturbances.
Used in Peripheral Vascular Disease Treatment:
Flunarizine dihydrochloride is used as a treatment for peripheral vascular disease, aiding in the improvement of blood circulation in the extremities.
Used in Vertigo Treatment:
Flunarizine dihydrochloride is used to treat vertigo, acting as a vestibular depressive agent to alleviate symptoms of dizziness and balance disorders.
Used in Calcium Channel Blocker Applications:
Flunarizine dihydrochloride is used as a calcium channel blocker, which helps in the regulation of calcium ion concentrations in cells, particularly useful in cardiovascular and neurological applications.
Used in Research:
Flunarizine dihydrochloride is used in scientific research to study its effects on high-potassium induced increases of intracellular free calcium, providing insights into cellular mechanisms and potential therapeutic applications.
Originator
Sibelium,Janssen,W. Germany,1977
Manufacturing Process
A mixture of 14.3 parts of di-(p-fluorophenyl)-chloromethane, 10.1 parts of 1-
cinnamylpiperazine, 12.7 parts of sodium carbonate, a few crystals of
potassium iodide in 200 parts of 4-methyl-2-pentanone is stirred and refluxed
for 21 hours. The reaction mixture is cooled and 50 parts of water are added.
The organic layer is separated, dried, filtered and evaporated.The oily residue is dissolved in 480 parts of anhydrous diisopropyl ether. This
solution is boiled with activated charcoal, filtered and to the clear filtrate is
added an excess of 2-propanol, previously saturated with gaseous hydrogen
chloride. The precipitated salt is filtered off and recrystallized from a mixture
of 2-propanol and ethanol, yielding 1-cinnamyl-4-(di-p-fluorobenzhydryl)
piperazine dihydrochloride, MP 251.5°C.
Therapeutic Function
Vasodilator
Biological Activity
Dual Na + /Ca 2+ channel blocker; a cerebral and peripheral vasodilator. Neuroprotective.
Biochem/physiol Actions
Blocks T-type Ca2+/Na+ channels; inhibits K+-induced catecholamine release from chromaffin cells
Check Digit Verification of cas no
The CAS Registry Mumber 30484-77-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,0,4,8 and 4 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 30484-77:
(7*3)+(6*0)+(5*4)+(4*8)+(3*4)+(2*7)+(1*7)=106
106 % 10 = 6
So 30484-77-6 is a valid CAS Registry Number.
InChI:InChI=1/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/p+2/b7-4+
30484-77-6Relevant academic research and scientific papers
(4-(Bis(4-Fluorophenyl)Methyl)Piperazin-1-yl)(Cyclohexyl) methanone hydrochloride (LDK1229): A new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs
Mahmoud, Mariam M.,Olszewska, Teresa,Liu, Hui,Shore, Derek M.,Hurst, Dow P.,Lu, Dai,Kendall, Debra A.
, p. 197 - 206 (2015/02/19)
Some inverse agonists of cannabinoid receptor type 1 (CB1) have been demonstrated to be anorectic antiobesity drug candidates. However, the first generation of CB1 inverse agonists, represented by rimonabant (SR141716A), otenabant, and taranabant, are centrally active, with a high level of psychiatric side effects. Hence, the discovery of CB1 inverse agonists with a chemical scaffold distinct from these holds promise for developing peripherally active CB1 inverse agonists with fewer side effects. We generated a new CB1 inverse agonist, (4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229), from the class of benzhydryl piperazine analogs. This compound binds to CB1 more selectively than cannabinoid receptor type 2, with a Ki value of 220 nM. Comparable CB1 binding was also observed by analogs 1-[bis(4-fluorophenyl)methyl]-4-cinnamylpiperazine dihydrochloride (LDK1203) and 1-[bis(4-fluorophenyl)methyl]-4-tosylpiperazine hydrochloride (LDK1222), which differed by the substitution on the piperazine ring where the piperazine of LDK1203 and LDK1222 are substituted by an alkyl group and a tosyl group, respectively. LDK1229 exhibits efficacy comparable with SR141716A in antagonizing the basal G protein coupling activity of CB1, as indicated by a reduction in guanosine 59-O-(3-thio)triphosphate binding. Consistent with inverse agonist behavior, increased cell surface localization of CB1 upon treatment with LDK1229 was also observed. Although docking and mutational analysis showed that LDK1229 forms similar interactions with the receptor as SR141716A does, the benzhydryl piperazine scaffold is structurally distinct from the first-generation CB1 inverse agonists. It offers new opportunities for developing novel CB1 inverse agonists through the optimization of molecular properties, such as the polar surface area and hydrophilicity, to reduce the central activity observed with SR141716A.
